-- 週五美股期貨盤前小幅走高,此前以色列和黎巴嫩在白宮舉行的由川普總統斡旋的會議上將停火期限延長了三週。 道瓊工業指數期貨下跌0.1%,標普500指數期貨上漲0.4%,那斯達克指數期貨下跌1.3%。 以色列與伊朗支持的黎巴嫩真主黨之間的衝突一直是中東衝突談判的關鍵議題。霍爾木茲海峽仍然對船隻關閉,而美國也繼續封鎖伊朗港口。 川普表示,他不急於與伊朗達成和平協議,並稱他希望達成的協議是「永久性的」。他延長了美伊停火協議,稱伊朗政府“四分五裂”,但伊朗最高領袖阿亞圖拉·穆傑塔巴·哈梅內伊週四否認了川普關於伊朗領導層不和的說法。 交易員們密切關注最新一輪的財報,寶潔公司(PG)公佈的第三財季業績增長,HCA醫療保健公司(HCA)第一財季調整後盈利和營收均有所增長。 油價基本持平,近月全球基準北海布蘭特原油期貨上漲0.3%,至每桶105.39美元;美國西德州中質原油期貨下跌0.1%,至每桶95.73美元。 根據彭博社總結的估計,定於美國東部時間上午10點公佈的密西根大學4月份消費者信心指數終值預計將達到48.5,高於先前公佈的47.6的初值。 在其他國際市場,日本日經指數收漲1%,香港恆生指數收漲0.2%,中國上證綜指收跌0.3%。同時,英國富時100指數下跌0.3%,德國DAX指數在歐洲午後交易時段上漲0.2%。 在股票方面,英特爾(INTC)股價上漲26%,此前該公司公佈了第一財季調整後盈利和營收,並發布了第二財季業績指引,均超出分析師預期。 AMD股價上漲11%,此前分析師DA Davidson將AMD股票評級從“中性”上調至“買入”,並將目標價從220美元上調至375美元。寶潔股價上漲2.6%,此前該公司公佈的第三財季業績超出分析師預期。 另一方面,HCA Healthcare股價下跌7.8%,此前該公司公佈了第一財季業績。康卡斯特 (CMCSA) 股價下跌 2.7%,此前該公司公佈的第一季調整後盈利低於去年同期。印孚瑟斯 (INFY) 股價下跌 2.6%,儘管該公司公佈的第四財季盈利和營收均有所增長。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.